German pharmaceutical company MorphoSys this week announced an agreement between its recently acquired subsidiary Sloning BioTechnology and Pfizer for the use of Sloning's Slonomics platform for the creation of gene and protein libraries.

The technology will be installed at Pfizer's subsidiary Rinat Neuroscience in South San Francisco. Per the arrangement, Morphosys will receive an upfront payment of an undisclosed amount this year, with the possibility of annual license fees over the patent lifetime of the Slonomics platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.